Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07500649

Project SIRT6 Activator

Sponsor: National University of Singapore

View on ClinicalTrials.gov

Summary

The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.

Official title: SIRT6 Activation to Improve Biological Age Measured by GrimAge in Pre-frail, Middle-aged to Older Men: a Randomized Controlled Trial

Key Details

Gender

MALE

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-07-01

Completion Date

2027-12-31

Last Updated

2026-03-30

Healthy Volunteers

Yes

Conditions

Aging

Interventions

DIETARY_SUPPLEMENT

Fucoidan

Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.

DIETARY_SUPPLEMENT

Placebo

Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.

Inclusion Criteria: 1. 50-80 years males; 2. Resident of Singapore (citizenship or permanent residency is not required); 3. Prefrail according to Fried frailty phenotype score; 4. English-literate who can understand, read and write in English; 5. Individuals without severe cognitive impairment, as determined by PI judgment; 6. Apparently healthy and non-smokers having not more than 2 of the following conditions. If the conditions are present they have to be stable: * Hypertension, * Hyperlipidemia, * Hyperglycemia, * Osteopenia/osteoporosis, * Osteoarthritis, * COPD, * Type 2 diabetes. Subjects who agree to shave one day before each visit if he has dense facial hairs on their cheeks that could interfere with skin microbiome sampling. Exclusion Criteria: 1. Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease); 2. Current cancer or non-stable chronic obstructive pulmonary disease (COPD); 3. Use of anticoagulant medication; 4. Consuming seaweed more than 3 times a week; 5. Having hairiness, moles, tattoos, scars, irritated skin, etc. on the face which could influence the investigation; 6. Having used within the 3 past weeks for more than 3 consecutive days any systemic or topical drugs related to antibiotics or having planned to use these treatments during the study; 7. Having a positive serology for HIV, HEPATITIS B, HEPATITIS C\* \*Subjects will undergo a serology test, which will be conducted at baseline and at the end of the intervention visit. Only for subjects who accepted to undergo skin microbiopsy sampling; 8. Subject with any contra-indication for skin microbiopsies: * hypersensitivity or any serious reaction to local anesthesia; (lidocaine/prilocaine), local antibiotics, and antiseptics, * with inherited or acquired hemostasis disorders, * having had any treatment which may affect the blood coagulation and hemostasis (anti-coagulant medications…), * having a history of wound healing defects (hypertrophic scars, keloids…).

Locations (2)

Yong Loo Lin School of Medicine, National University of Singapore

Singapore, Singapore, Singapore

NUS Academy for Healthy Longevity, Level 6, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore

Singapore, Singapore